GB9501841D0
(en)
*
|
1995-01-31 |
1995-03-22 |
Co Ordinated Drug Dev |
Improvements in and relating to carrier particles for use in dry powder inhalers
|
GB9515182D0
(en)
*
|
1995-07-24 |
1995-09-20 |
Co Ordinated Drug Dev |
Improvements in and relating to powders for use in dry powder inhalers
|
GB9703673D0
(en)
*
|
1997-02-21 |
1997-04-09 |
Bradford Particle Design Ltd |
Method and apparatus for the formation of particles
|
US20070212422A1
(en)
*
|
1999-11-10 |
2007-09-13 |
Manfred Keller |
Dry powder for inhalation
|
US20060171899A1
(en)
*
|
1998-12-10 |
2006-08-03 |
Akwete Adjei |
Water-stabilized aerosol formulation system and method of making
|
IT1309592B1
(it)
*
|
1999-03-05 |
2002-01-24 |
Chiesi Farma Spa |
Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
|
HUP0200185A3
(en)
*
|
1999-03-05 |
2006-07-28 |
Chiesi Farma Spa |
Improved powdery pharmaceutical compositions for inhalation
|
PE20011227A1
(es)
*
|
2000-04-17 |
2002-01-07 |
Chiesi Farma Spa |
Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
|
GB0009468D0
(en)
*
|
2000-04-17 |
2000-06-07 |
Vectura Ltd |
Improvements in or relating to formulations for use in inhaler devices
|
GB0009469D0
(en)
*
|
2000-04-17 |
2000-06-07 |
Vectura Ltd |
Improvements in or relating to formalities for use in inhaler devices
|
GB0012261D0
(en)
|
2000-05-19 |
2000-07-12 |
Astrazeneca Ab |
Novel process
|
GB0012260D0
(en)
|
2000-05-19 |
2000-07-12 |
Astrazeneca Ab |
Novel composition
|
PT1296651E
(pt)
|
2000-06-27 |
2008-02-12 |
Vectura Ltd |
Método para fazer partículas para serem usadas numa composição farmacêutica
|
GB0027357D0
(en)
*
|
2000-11-09 |
2000-12-27 |
Bradford Particle Design Plc |
Particle formation methods and their products
|
AU2002222118A1
(en)
†
|
2000-11-30 |
2002-06-11 |
Vectura Limited |
Pharmaceutical compositions for inhalation
|
EP3269360A1
(en)
|
2000-11-30 |
2018-01-17 |
Vectura Limited |
Method of making particles for use in a pharmaceutical composition
|
ATE446085T1
(de)
*
|
2000-11-30 |
2009-11-15 |
Vectura Ltd |
Partikel zur verwendung in einer pharmazeutischen zusammensetzung
|
WO2002056948A1
(en)
|
2001-01-17 |
2002-07-25 |
Vectura Limited |
An inhaler device
|
GB0208742D0
(en)
|
2002-04-17 |
2002-05-29 |
Bradford Particle Design Ltd |
Particulate materials
|
AU2002333644A1
(en)
|
2001-09-17 |
2003-04-01 |
Glaxo Group Limited |
Dry powder medicament formulations
|
US7931533B2
(en)
|
2001-09-28 |
2011-04-26 |
Igt |
Game development architecture that decouples the game logic from the graphics logics
|
SE0200312D0
(sv)
*
|
2002-02-01 |
2002-02-01 |
Astrazeneca Ab |
Novel composition
|
US20050191357A1
(en)
*
|
2002-03-20 |
2005-09-01 |
Yoshiaki Kawashima |
Method of manufacturing chemical-containing composite particles
|
FI116657B
(fi)
*
|
2002-03-28 |
2006-01-31 |
Focus Inhalation Oy |
Menetelmä kantoainehiukkasten käsittelemiseksi ja niiden käyttö
|
US20030235538A1
(en)
*
|
2002-04-09 |
2003-12-25 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Method for the administration of an anticholinergic by inhalation
|
US7582284B2
(en)
*
|
2002-04-17 |
2009-09-01 |
Nektar Therapeutics |
Particulate materials
|
GB0216562D0
(en)
|
2002-04-25 |
2002-08-28 |
Bradford Particle Design Ltd |
Particulate materials
|
US9339459B2
(en)
|
2003-04-24 |
2016-05-17 |
Nektar Therapeutics |
Particulate materials
|
ATE520405T1
(de)
*
|
2002-08-21 |
2011-09-15 |
Norton Healthcare Ltd |
Inhalationszusammensetzung
|
AU2003263717A1
(en)
*
|
2002-09-25 |
2004-04-19 |
Astrazeneca Ab |
A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
EP1452179A1
(en)
*
|
2003-02-27 |
2004-09-01 |
CHIESI FARMACEUTICI S.p.A. |
Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
|
WO2004093848A2
(en)
*
|
2003-04-14 |
2004-11-04 |
Vectura Ltd |
Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
|
US20060147389A1
(en)
*
|
2004-04-14 |
2006-07-06 |
Vectura Ltd. |
Devices and pharmaceutical compositions for enhancing dosing efficiency
|
US7094545B2
(en)
*
|
2003-04-30 |
2006-08-22 |
Ferring Bv |
Pharmaceutical composition as solid dosage form and method for manufacturing thereof
|
EP1646370A1
(en)
*
|
2003-07-11 |
2006-04-19 |
Glaxo Group Limited |
Pharmaceutical formulations
|
WO2005004845A1
(en)
*
|
2003-07-11 |
2005-01-20 |
Glaxo Group Limited |
Pharmaceutical formulations comprising magnesium stearate
|
SI1500390T1
(sl)
*
|
2003-07-25 |
2006-02-28 |
Ferring Bv |
Farmacevtski dezmopresinski sestavek kot trdna dozirna oblika in postopek za njegovo pripravo
|
CN1826099B
(zh)
*
|
2003-07-25 |
2010-06-09 |
凡林有限公司 |
固体剂型药物组合物及其制造方法
|
EP1663164A2
(en)
*
|
2003-09-15 |
2006-06-07 |
Vectura Limited |
Methods for preparing pharmaceutical compositions
|
GB0321607D0
(en)
|
2003-09-15 |
2003-10-15 |
Vectura Ltd |
Manufacture of pharmaceutical compositions
|
GB0327723D0
(en)
|
2003-09-15 |
2003-12-31 |
Vectura Ltd |
Pharmaceutical compositions
|
GB0324918D0
(en)
*
|
2003-10-24 |
2003-11-26 |
Glaxo Group Ltd |
Composition
|
GB0326632D0
(en)
*
|
2003-11-14 |
2003-12-17 |
Jagotec Ag |
Dry powder formulations
|
SE0303570L
(sv)
*
|
2003-12-03 |
2005-06-04 |
Microdrug Ag |
Fukt-känslig medicinsk produkt
|
CA2547782A1
(en)
*
|
2003-12-03 |
2005-06-16 |
Microdrug Ag |
Medical product containing tiotropium
|
SE0303270L
(sv)
*
|
2003-12-03 |
2005-06-04 |
Microdrug Ag |
Metod för administration av tiotropium
|
SE0303569L
(sv)
*
|
2003-12-03 |
2005-06-04 |
Microdrug Ag |
DPI för avlämning av fuktkänsliga medikament
|
SE0303571D0
(sv)
*
|
2003-12-03 |
2003-12-22 |
Microdrug Ag |
Medical product for moisture-sensitive medicaments
|
SE0303269L
(sv)
*
|
2003-12-03 |
2005-06-04 |
Microdrug Ag |
Medicinsk produkt
|
US7018653B2
(en)
*
|
2003-12-29 |
2006-03-28 |
Ferring B.V. |
Method for preparing solid dosage form of desmopressin
|
JO3102B1
(ar)
*
|
2004-03-17 |
2017-09-20 |
Chiesi Framaceutici S P A |
صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
|
EP2708225B1
(en)
*
|
2004-04-23 |
2018-12-26 |
CyDex Pharmaceuticals, Inc. |
DPI Formulation Containing Sulfoalkyl Ether Cyclodextrin
|
GB0409703D0
(en)
|
2004-04-30 |
2004-06-02 |
Vectura Ltd |
Pharmaceutical compositions
|
GB0425758D0
(en)
|
2004-11-23 |
2004-12-22 |
Vectura Ltd |
Preparation of pharmaceutical compositions
|
GB0426301D0
(en)
*
|
2004-11-30 |
2004-12-29 |
Vectura Ltd |
Pharmaceutical formulations
|
BRPI0606364A2
(pt)
|
2005-02-10 |
2010-03-23 |
Glaxo Group Ltd |
processo para formar lactose adequada para uso em uma formulaÇço farmacÊutica
|
US20090022915A1
(en)
*
|
2005-03-09 |
2009-01-22 |
Ono Pharmaceutical Co., Ltd., |
Particle and preparation containing the particle
|
CA2603433A1
(en)
*
|
2005-03-30 |
2006-10-05 |
Schering Corporation |
Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
|
TWI274641B
(en)
*
|
2005-08-30 |
2007-03-01 |
Rexon Ind Corp Ltd |
Cutting machine
|
US7629331B2
(en)
|
2005-10-26 |
2009-12-08 |
Cydex Pharmaceuticals, Inc. |
Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
|
GB0525254D0
(en)
|
2005-12-12 |
2006-01-18 |
Jagotec Ag |
Powder compositions for inhalation
|
GB0613161D0
(en)
*
|
2006-06-30 |
2006-08-09 |
Novartis Ag |
Organic Compounds
|
GB0622818D0
(en)
*
|
2006-11-15 |
2006-12-27 |
Jagotec Ag |
Improvements in or relating to organic compounds
|
EP1944018A1
(en)
*
|
2007-01-10 |
2008-07-16 |
CHIESI FARMACEUTICI S.p.A. |
Micronised particles of low-dosage strength active agents for powder formulations for inhalation
|
JP5825757B2
(ja)
|
2007-02-11 |
2015-12-02 |
マップ・ファーマシューティカルズ・インコーポレイテッド |
副作用プロファイルを最小限にしながら片頭痛の迅速な緩和を可能にするdheの治療上の投与方法
|
NZ582586A
(en)
|
2007-07-21 |
2011-12-22 |
Albany Molecular Res Inc |
5-pyridinone substituted indazoles
|
US20090136473A1
(en)
|
2007-11-21 |
2009-05-28 |
Decode Genetics Ehf |
Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders
|
BRPI0907122B8
(pt)
|
2008-01-11 |
2021-05-25 |
Albany Molecular Res Inc |
compostos de piridoindóis (1-azinona) substituídos, composição farmacêutica compreendendo os referidos compostos, e usos dos mesmos
|
CA2711865A1
(en)
|
2008-01-11 |
2009-07-16 |
Astellas Pharma Inc. |
A pathological animal model simultaneously developing testicular pain or discomfort behaviors and urinary frequency
|
EP2080508A1
(en)
|
2008-01-15 |
2009-07-22 |
CHIESI FARMACEUTICI S.p.A. |
Dry powder formulation comprising an anticholinergic drug
|
WO2010059836A1
(en)
|
2008-11-20 |
2010-05-27 |
Decode Genetics Ehf |
Substituted aza-bridged bicyclics for cardiovascular and cns disease
|
EP2191821A1
(en)
|
2008-11-26 |
2010-06-02 |
CHIESI FARMACEUTICI S.p.A. |
Microparticles comprising a salt of 8-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone having improved adhesion properties for dry powder inhalation
|
BRPI1007350B8
(pt)
|
2009-01-26 |
2021-05-25 |
Israel Institute For Biological Res |
compostos espiro heterocíclicos bicíclicos
|
US9925282B2
(en)
|
2009-01-29 |
2018-03-27 |
The General Hospital Corporation |
Cromolyn derivatives and related methods of imaging and treatment
|
WO2010097188A1
(en)
|
2009-02-25 |
2010-09-02 |
Chiesi Farmaceutici S.P.A. |
Inhalation particles comprising a salt of carmoterol and a corticosteroid
|
PT2400950T
(pt)
|
2009-02-26 |
2019-08-29 |
Glaxo Group Ltd |
Formulações farmacêuticas compreendendo 4-{(1r)-2-[(6-{2-[(2,6-diclorobenzil)oxi]ethoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
|
EP2421514A2
(en)
*
|
2009-04-24 |
2012-02-29 |
Schering Corporation |
Agglomerate formulations useful in dry powder inhalers
|
WO2011015289A1
(en)
|
2009-08-04 |
2011-02-10 |
Chiesi Farmaceutici S.P.A. |
8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl] amino]ethyl]-2(1h)-quinolinone hemi-fumarate
|
GB0918249D0
(en)
|
2009-10-19 |
2009-12-02 |
Respivert Ltd |
Compounds
|
GB0921075D0
(en)
|
2009-12-01 |
2010-01-13 |
Glaxo Group Ltd |
Novel combination of the therapeutic agents
|
EP2360147A1
(en)
|
2010-02-22 |
2011-08-24 |
CHIESI FARMACEUTICI S.p.A. |
Process for preparing crystalline particles of a salt of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-quinolinone (carmoterol)
|
JP5927175B2
(ja)
|
2010-04-01 |
2016-06-01 |
シエシー ファルマセウティチィ ソシエタ ペル アチオニ |
ドライパウダー状の吸入用医薬組成物、担体粒子および医薬品の製造方法
|
RU2580312C2
(ru)
*
|
2010-04-21 |
2016-04-10 |
КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. |
Способ получения частиц с пониженным электростатическим зарядом
|
SI2563813T1
(sl)
|
2010-04-30 |
2015-12-31 |
Alexion Pharmaceuticals, Inc. |
Protitelesa anti-C5A in postopki uporabe protiteles
|
US9259376B2
(en)
|
2010-06-03 |
2016-02-16 |
Sima Patent Ve Lisanslama Hizmetleri Ltd. Sti. |
Process for dry powder formulations
|
PE20130282A1
(es)
*
|
2010-06-22 |
2013-03-25 |
Chiesi Farma Spa |
Formulacion en polvo seca que comprende una droga antimuscarinica
|
JP6004233B2
(ja)
*
|
2010-08-03 |
2016-10-05 |
チェシ ファーマスーティシ エス.ピー.エイ. |
ホスホジエステラーゼ阻害剤を含む乾燥粉末製剤
|
EP2611416B1
(en)
*
|
2010-09-03 |
2015-08-19 |
Pharmaterials Ltd. |
Pharmaceutical composition suitable for use in a dry powder inhaler
|
BR112013007304B1
(pt)
|
2010-09-29 |
2021-12-14 |
Pulmatrix, Inc. |
Pós secos de cátion de metal monovalente para inalação
|
KR101886987B1
(ko)
|
2010-09-30 |
2018-08-08 |
키에시 파르마슈티시 엣스. 피. 에이. |
흡입용 건조 분말 제제 내 마그네슘 스테아레이트의 용도
|
UY33337A
(es)
|
2010-10-18 |
2011-10-31 |
Respivert Ltd |
DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
|
CA2767773C
(en)
|
2011-02-11 |
2015-11-24 |
Grain Processing Corporation |
Composition comprising a salt and a crystallization interrupter
|
TR201105367A2
(tr)
*
|
2011-06-02 |
2012-12-21 |
Bi̇lgi̇ç Mahmut |
Akış özellikleri geliştirilmiş bir kuru toz formülasyonu.
|
TR201205852A2
(tr)
*
|
2011-06-02 |
2012-12-21 |
Bi̇lgi̇ç Mahmut |
Geliştirilmiş yeni kuru toz formülasyonu.
|
WO2013109215A1
(en)
*
|
2012-01-16 |
2013-07-25 |
Mahmut Bilgic |
Preparation of dry powder formulations comprising formoterol
|
WO2013109211A1
(en)
*
|
2012-01-16 |
2013-07-25 |
Mahmut Bilgic |
Dry powder formulations comprising r-formoterol as active agent
|
WO2013109210A1
(en)
*
|
2012-01-16 |
2013-07-25 |
Mahmut Bilgic |
Dry powder formulations comprising budesonide
|
PT3527199T
(pt)
|
2012-01-25 |
2022-11-08 |
Chiesi Farm Spa |
Formulação de um pó seco compreendendo um corticosteroide e um beta adrenérgico para administração por inalação
|
EP2809780B1
(en)
|
2012-02-01 |
2018-05-02 |
Protalix Ltd. |
Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
|
NZ629722A
(en)
|
2012-02-29 |
2017-03-31 |
Pulmatrix Operating Co Inc |
Inhalable dry powders
|
SG11201404519UA
(en)
|
2012-03-13 |
2014-10-30 |
Respivert Ltd |
Novel pharmaceutical formulations
|
KR20140147891A
(ko)
|
2012-04-13 |
2014-12-30 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
응집체 입자
|
WO2014007771A2
(en)
|
2012-07-05 |
2014-01-09 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Inhalation compositions comprising muscarinic receptor antagonist
|
US10111957B2
(en)
*
|
2012-07-05 |
2018-10-30 |
Arven Ilac Snayi ve Ticaret A.S. |
Inhalation compositions comprising glucose anhydrous
|
EP3563849A3
(en)
|
2012-10-25 |
2020-02-12 |
The General Hospital Corporation |
Combination therapies for the treatment of alzheimer's disease and related disorders
|
US11052202B2
(en)
|
2012-11-07 |
2021-07-06 |
Chiesi Farmaceutici S.P.A. |
Drug delivery device for the treatment of patients with respiratory diseases
|
US9757529B2
(en)
|
2012-12-20 |
2017-09-12 |
Otitopic Inc. |
Dry powder inhaler and methods of use
|
US9757395B2
(en)
|
2012-12-20 |
2017-09-12 |
Otitopic Inc. |
Dry powder inhaler and methods of use
|
BR112015017784A2
(pt)
|
2013-01-28 |
2017-07-11 |
Incozen Therapeutics Pvt Ltd |
método para tratar distúrbios autoimunes, respiratórios e inflamatórios por inalação de n-óxido de roflumilast
|
GB201305825D0
(en)
|
2013-03-28 |
2013-05-15 |
Vectura Ltd |
New use
|
CA2897334A1
(en)
|
2013-03-29 |
2014-10-02 |
Alexion Pharmaceuticals, Inc. |
Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
|
WO2014178891A1
(en)
|
2013-04-30 |
2014-11-06 |
Otitopic Inc. |
Dry powder formulations and methods of use
|
US10525005B2
(en)
|
2013-05-23 |
2020-01-07 |
The General Hospital Corporation |
Cromolyn compositions and methods thereof
|
EP2821061B1
(en)
*
|
2013-07-01 |
2017-12-20 |
Arven Ilac Sanayi Ve Ticaret A.S. |
Novel inhalation formulations
|
DK3019153T3
(en)
*
|
2013-07-11 |
2018-11-19 |
Chiesi Farm Spa |
Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for inhalation administration
|
EP3052092A2
(en)
*
|
2013-10-02 |
2016-08-10 |
Vectura Limited |
Method and apparatus
|
US9427376B2
(en)
*
|
2013-10-10 |
2016-08-30 |
Chiesi Farmaceutici S.P.A. |
Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
|
AU2014340182B2
(en)
|
2013-10-22 |
2019-05-23 |
The General Hospital Corporation |
Cromolyn derivatives and related methods of imaging and treatment
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
US9554992B2
(en)
|
2014-06-09 |
2017-01-31 |
Chiesi Farmaceutici S.P.A. |
Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
|
EP2957552B1
(en)
|
2014-06-16 |
2020-01-22 |
Arven Ilac Sanayi Ve Ticaret A.S. |
Vilanterol formulations
|
TR201407010A2
(tr)
|
2014-06-16 |
2015-12-21 |
Arven Ilac Sanayi Ve Ticaret Anonim Sirketi |
Vilanterol formülasyonları.
|
US20180021256A1
(en)
*
|
2014-07-09 |
2018-01-25 |
Arven Ilac Sanayi Ve Ticaret A.S. |
Process for the preparation of formulations for inhalation
|
US20170304459A1
(en)
|
2014-10-10 |
2017-10-26 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhalation delivery of conjugated oligonucleotide
|
CN107106641B
(zh)
|
2014-10-31 |
2021-12-21 |
葛兰素史密斯克莱知识产权发展有限公司 |
粉末制剂
|
RU2693201C1
(ru)
*
|
2015-06-23 |
2019-07-01 |
Шлюмберже Текнолоджи Б.В. |
Распознание расклинивающего агента с помощью мобильного устройства
|
US11224594B2
(en)
*
|
2015-09-16 |
2022-01-18 |
Philip Morris Products S.A. |
Nicotine formulations and methods of making and using the same
|
CA3005291C
(en)
*
|
2015-11-16 |
2024-01-16 |
Chiesi Farmaceutici S.P.A. |
A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
|
ES2783855T3
(es)
|
2015-11-16 |
2020-09-18 |
Chiesi Farm Spa |
Un proceso para preparar una formulación de polvo seco que comprende un anticolinérgico, un corticoesteroide y un beta-adrenérgico
|
BR112018010830B1
(pt)
*
|
2015-12-24 |
2023-04-11 |
Philip Morris Products S.A. |
Cápsula de partícula de nicotina
|
AU2017321782B2
(en)
|
2016-08-31 |
2022-03-10 |
The General Hospital Corporation |
Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
|
ES2882153T3
(es)
*
|
2017-05-11 |
2021-12-01 |
Chiesi Farm Spa |
Un proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un betaadrenérgico
|
KR20220155395A
(ko)
*
|
2017-05-11 |
2022-11-22 |
키에시 파르마슈티시 엣스. 피. 에이. |
항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제의 제조 방법
|
US10583085B2
(en)
|
2017-05-17 |
2020-03-10 |
Chiesi Farmaceutici S.P.A. |
Carrier particles for dry powder formulations for inhalation
|
EA202090247A1
(ru)
|
2017-07-14 |
2020-05-12 |
Цитомкс Терапьютикс, Инк. |
Антитела против cd166 и их применения
|
WO2019019040A1
(en)
*
|
2017-07-26 |
2019-01-31 |
Shenzhen Xpectvision Technology Co., Ltd. |
SYSTEM HAVING SPATIALLY EXPANDED X-RAY SOURCE FOR X-RAY IMAGING
|
DK3658184T5
(da)
|
2017-07-27 |
2024-08-26 |
Alexion Pharma Inc |
Højkoncentrerede anti-c5-antistofformuleringer
|
WO2019060604A1
(en)
|
2017-09-20 |
2019-03-28 |
Teva Branded Pharmaceutical Products R&D, Inc. |
INHALABLE MEDICINE
|
US10786456B2
(en)
|
2017-09-22 |
2020-09-29 |
Otitopic Inc. |
Inhaled aspirin and magnesium to treat inflammation
|
WO2019059953A2
(en)
|
2017-09-22 |
2019-03-28 |
Otitopic Inc. |
DRY POWDER COMPOSITIONS CONTAINING MAGNESIUM STEARATE
|
WO2019060797A1
(en)
|
2017-09-22 |
2019-03-28 |
Teva Branded Pharmaceutical Products R&D, Inc. |
PROCESS FOR PRODUCING POWDERS FOR INHALING
|
WO2019067708A1
(en)
*
|
2017-09-27 |
2019-04-04 |
Teva Branded Pharmaceutical Products R&D, Inc. |
METHOD FOR DECREASING PARTICLE SIZE
|
CA3105392A1
(en)
*
|
2018-07-02 |
2020-01-09 |
The General Hospital Corporation |
Powdered formulations of cromolyn sodium and .alpha.-lactose
|
WO2020020957A1
(en)
|
2018-07-27 |
2020-01-30 |
Chiesi Farmaceutici S.P.A. |
Novel carrier particles for dry powder formulations for inhalation
|
CN112789037A
(zh)
|
2018-09-06 |
2021-05-11 |
创新药物筛选有限公司 |
用于治疗哮喘或帕金森病的方法和药物组合物
|
MX2021004643A
(es)
|
2018-10-30 |
2021-05-28 |
Chiesi Farm Spa |
Aparato para administrar farmacos a pacientes ventilados mecanicamente.
|
CN113412117A
(zh)
|
2018-12-12 |
2021-09-17 |
凯德药业股份有限公司 |
嵌合抗原和t细胞受体及使用的方法
|
BR112021021775A2
(pt)
|
2019-04-29 |
2022-01-04 |
Insmed Inc |
Composições de pó seco de pró-fármacos de treprostinil e métodos de uso destas
|
BR112022004970A2
(pt)
|
2019-09-24 |
2022-08-23 |
Chiesi Farm Spa |
Formulação de pó seco, processo para preparar uma formulação de pó seco e inalador de pó seco
|
BR112022021450A2
(pt)
|
2020-04-24 |
2022-12-27 |
Millennium Pharm Inc |
O cd19 ou fragmento de ligação, método de tratamento de um câncer, composição farmacêutica, ácido nucleico, vetor, e, célula isolada
|
WO2021237109A1
(en)
|
2020-05-22 |
2021-11-25 |
Trailhead Biosystems Inc. |
Combination therapy for treatment of viral infections
|
CN112451509B
(zh)
*
|
2020-12-19 |
2023-03-07 |
沈阳药科大学 |
一种川丁特罗吸入粉雾剂及其制备方法
|
JP2024515066A
(ja)
|
2021-04-09 |
2024-04-04 |
武田薬品工業株式会社 |
補体因子dを標的とする抗体及びその使用
|
CN117580860A
(zh)
|
2021-04-26 |
2024-02-20 |
米伦纽姆医药公司 |
抗adgre2抗体及其用途
|
AU2022266584A1
(en)
|
2021-04-26 |
2023-10-12 |
Millennium Pharmaceuticals, Inc. |
Anti-clec12a antibodies and uses thereof
|
WO2023068382A2
(en)
|
2021-10-20 |
2023-04-27 |
Takeda Pharmaceutical Company Limited |
Compositions targeting bcma and methods of use thereof
|
CN118414147A
(zh)
|
2021-12-21 |
2024-07-30 |
凯西制药公司 |
填充在具有改善的耐湿性的吸入器中的干粉制剂
|
CN118475343A
(zh)
|
2021-12-21 |
2024-08-09 |
凯西制药公司 |
填充在具有改善的耐湿性的吸入器中的干粉制剂
|
WO2023150747A1
(en)
|
2022-02-07 |
2023-08-10 |
Insmed Incorporated |
Dry powder compositions of bedaquiline and salts and methods of use thereof
|
WO2024062007A1
(en)
|
2022-09-22 |
2024-03-28 |
Chiesi Farmaceutici S.P.A. |
Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
|